Biomarkers and Pathology

One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

    Related Conference of Biomarkers and Pathology

    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 20-21, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Biomarkers and Pathology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in